A multicenter, randomized, controlled clinical trial to explore the effect of 5-Fluorouracil combine

来源 :第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 | 被引量 : 0次 | 上传用户:yangyinxia_email
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Objective: The prognosis for unresectable metastatic colorectal cancers is poor, and improved therapies are needed.Recent studies have shown the activated NLRP3 inflammasome was one of the machanism that responsible for the resistance to 5-FU.
其他文献
  Objective: Patients were excluded if they were older than 75 years of age in most clinical trials.Thus, the optimal treatment strategies in elderly patients
会议
  Objective: To retrospectively evaluate the safety and efficacy of radiofrequency ablation (RFA) following trans arterial chemoembolization (TACE) for patien
会议
  Objective: The purpose of this study is to develop a predictive nomogram to improve the diagnostic accuracy and inter-observer agreement of pre-therapeutic
会议
  Objective: Despite the improved patient care and the declined mortality rate, gastric cancer is still a leading cause of cancer deaths worldwide, particular
会议
  Objective: To evaluate the value of lymph node status of primary tumors in predicting the prognosis of synchronous resectable metastatic colorectal cancer (
会议
  Objective: To evaluate the maximum tolerated dose (MTD) of concurrent capecitabine with preoperative radiation (RT) in elderly patients with rectal cancer,
会议
  Objective: To investigate the relations of preoperative body mass index (BMI) with the change in BMI during perioperative period and disease-free survival (
会议
  Objective: Our aim was to determine impact of negative to positive lymph node ratio (NPR) on oncological outcomes in a series of patients with stage Ⅲ colo
会议
  Objective: To describe and analyze the clinicalpathological features, treatments and survival of Chinese patients with small intestine neuroendocrine tumors
会议
  Objective: Patients with metastatic colorectal cancer are now recommended to profile for RAS and BRAF mutations before receiving cetuximab or panitumumab.Ho
会议